Memantine benefits functional abilities in moderate to severe Alzheimer’s disease
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Functional abilities are severely impacted in Alzheimer’s disease (AD). Loss of the ability to perform complex (instrumental) and basic activities of daily living (ADL), leads to decreased independence and increased caregiver burden. This post-hoc analysis investigated the effect of memantine (20 mg/day) on ADLs, as measured by Alzheimer’s Disease Cooperative Study-Activities of Daily Living 19-item (ADCSADL19) and 23-item (ADCS-ADL23) scales, in patients with moderate-to-severe AD.
Data were pooled from six multicenter, randomized, placebo-controlled, double-blind, 6-month studies of memantine 20 mg/day.
Male and female patients aged ≥50 years at baseline with a Mini Mental State Examination (MMSE) score <20.
ADCS-ADL19 and ADCS-ADL23 scales were pooled, and 14 shared items, with a score range of 0–45, were identified and included in the analysis (ADL14). Basic ADLs (BADLs) were defined as: eating, walking, toileting, bathing, and grooming. Instrumental ADLs (IADLs) were defined as: using a telephone, watching television, conversing, clearing a table, finding belongings, obtaining a beverage, disposing of household rubbish, travelling outside the house, and being left alone. Changes from baseline on single-item, BADL (range: 0–15), IADL (range: 0–30), and total ADL14 scores were analysed for observed cases using ANCOVA, with study, center and treatment as categorical explanatory variables and score at baseline as a covariate.
959 patients were treated with memantine and 867 patients received placebo. Memantine-treated patients had less decline from baseline on the ADL14 total score, compared with placebo (p<0.001) at study end. Memantine also showed lower reductions in BADLs (p<0.05) and IADLs (p<0.001), for observed cases, compared with placebo. Memantine-treated patients showed less worsening than placebo recipients for the ADL items: toileting (p<0.01), grooming (p<0.01), finding belongings (p<0.01), and travelling outside the house (p<0.05).
Compared with placebo, memantine shows benefits for both basic and instrumental ADLs in patients with moderate-to-severe AD, suggesting that memantine treatment may lead to a more interactive and dignified life for patients with moderate-to-severe AD.
- Cummings JL. Alzheimer’s disease. N Engl J Med. 2004;351:56–67. CrossRef
- Galasko D, Schmitt F, Thomas R, Jin S, Bennett D. Detailed assessment of activities of daily living in moderate to severe Alzheimer’s disease. J Int Neuropsychol Soc. 2005;11:446–453.
- Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54(Suppl 5):S4–S9.
- Smith GE, O’Brien PC, Ivnik RJ, Kokmen E, Tangalos EG. Prospective analysis of risk factors for nursing home placement of dementia patients. Neurology. 2001;57:1467–1473.
- Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA. 2002;287:2090–2097. CrossRef
- Georges J, Jansen S, Jackson J, Meyrieux A, Sadowska A, Selmes M. Alzheimer’s disease in real life-the dementia carer’s survey. Int J Geriatr Psychiatry. 2008;23:546–551. CrossRef
- Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int J Geriatr Psychiatry. 2003;18,(Suppl 1):S23–S32. CrossRef
- Lipton SA. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer’s disease and other neurologic disorders. J Alzheimers Dis. 2004;6(Suppl):S61–S74.
- Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer’s disease: tolerability and safety data from clinical trials. Drug Saf. 2008;31:577–585. CrossRef
- Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008;23:537–545. CrossRef
- Winblad B, Jones RW, Wirth Y, Stoffler A, Mobius HJ. Memantine in moderate to severe Alzheimer’s disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007;24:20–27. CrossRef
- Mecocci P, Bladstrom A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer’s disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry. 2009;24:532–538. CrossRef
- Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14:135–146. CrossRef
- Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology. 2007;69:459–469. CrossRef
- Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, et al. Long-term safety and efficacy of donepezil in patients with severe Alzheimer’s disease: results from a 52-week, open-label, multicenter, extension study in Japan. Dement Geriatr Cogn Disord. 2009;27:232–239. CrossRef
- Winblad B, Kilander L, Eriksson S, Minthon L, Båtsman L, Wetterholm A-L, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet, 2006:367:1057–1065 CrossRef
- Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer’s disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimers Dis. 2007;11:471–479.
- Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006;14:704–715. CrossRef
- Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348:1333–1341. CrossRef
- Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317–324. CrossRef
- van Dyck CH, Tariot PN, Meyers B, Malca Resnick E. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21:136–143. CrossRef
- Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT. Memantine treatment in patients with mild to moderate Alzheimer’s disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5:83–89. CrossRef
- Criteria for the clinical diagnosis of Alzheimer’s disease. Excerpts from the NINCDS-ADRDA Work Group report. J Am Geriatr Soc. 1985;33:2–3.
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–944.
- Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22:209–221. CrossRef
- Robinson DM, Keating GM. Memantine: a review of its use in Alzheimer’s disease. Drugs. 2006;66:1515–1534. CrossRef
- Wimo A, Winblad B, Stoffler A, Wirth Y, Mobius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer’s disease. Pharmacoeconomics. 2003;21:327–340. CrossRef
- Rive B, Vercelletto M, Damier FD, Cochran J, Francois C. Memantine enhances autonomy in moderate to severe Alzheimer’s disease. Int J Geriatr Psychiatry. 2004;19:458–464. CrossRef
- Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80:600–607. CrossRef
- Memantine benefits functional abilities in moderate to severe Alzheimer’s disease
The journal of nutrition, health & aging
Volume 14, Issue 9 , pp 770-774
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Alzheimer’s disease
- functional ability
- Industry Sectors
- Author Affiliations
- 1. Karolinska Institutet, Alzheimer Disease Research Center (KI-ADRC) NOVUM, Huddinge, Sweden
- 4. Karolinska Institutet, Alzheimer Disease Research Center (KI-ADRC) NOVUM, Floor 5, S-14157, Huddinge, Sweden
- 2. McGill Center for Studies in Aging, Douglas Institute for Mental Health, Montreal, Quebec, Canada
- 3. H. Lundbeck A/S, Copenhagen, Denmark